摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-amino-5-(4-hydroxyphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile | 896930-47-5

中文名称
——
中文别名
——
英文名称
7-amino-5-(4-hydroxyphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
英文别名
7-amino-5-(4-hydroxyphenyl)-2,4-dioxo-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile
7-amino-5-(4-hydroxyphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile化学式
CAS
896930-47-5
化学式
C14H10N4O4
mdl
——
分子量
298.258
InChiKey
ZZNVDDZGPIFNDE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    138
  • 氢给体数:
    4
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    7-amino-5-(4-hydroxyphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile1-(but-3-ynyl)-4-(3-fluoropropyl)piperazinecopper(ll) sulfate pentahydrate四丁基溴化铵sodium ascorbate 、 3,7-diazabicyclo[3.3.1]nonane 、 三异丙基硅烷三氟乙酸 作用下, 以 N,N-二甲基甲酰胺甲醇 为溶剂, 反应 76.5h, 以77%的产率得到N-(5-(4-(2-(4-(3-fluoropropyl)piperazin-1-yl)ethyl)-1H-1,2,3-triazol-1-yl)pentanamido)-SNEWILPRLPQH
    参考文献:
    名称:
    使用CuAAC Click化学方法对SNEW肽进行放射性氟化的高效生物正交策略及其铜耗竭的作用
    摘要:
    已知EphB2受体在各种类型的癌症中均过表达,因此是通过正电子发射断层扫描(PET)进行肿瘤细胞成像的有希望的靶标。在这方面,影像学可以促进早期发现EphB2过表达的肿瘤,监测针对EphB2的治疗反应,从而改善患者预后。我们报告了几种含有SNEW氨基酸基序,对EphB2受体具有高亲和力的,带有氟新标记的氟18标记肽的合成和评估,这些肽在使用PET进行的癌症无创成像中具有作为放射性示踪剂的潜力。出于放射性氟化的目的,通过引入L改变了Cph端的EphB2拮抗SNEW肽半胱氨酸,以及炔烃或叠氮化物修饰的氨基酸。此外,还应用了两种新型的双功能和生物正交标记构建基[ 18 F] AFP和[ 18 F] BFP,并将它们引入氟18的能力与已建立的[ 18 F] FBAM构建基进行了比较。铜辅助的Huisgen 1,3-偶极环加成反应属于生物正交点击化学反应,可在温和条件下将这两种新型结构单元引入叠氮化
    DOI:
    10.1002/cmdc.201300053
  • 作为产物:
    参考文献:
    名称:
    乙醇水溶液中声化学合成烯醇化羰基及其类似物的亚苄基衍生物
    摘要:
    这项工作描述了在乙醇水溶液中使用有机催化剂高效、简洁、绿色地声化学合成烯醇化羰基的亚苄基衍生物,其中包括巴比妥酸衍生物、吡唑-5-酮和绕丹宁。该方法能够通过烯醇化羰基的直接 sp 3 C–H 烯化反应合成各种亚苄基衍生物。我们非常强调这些衍生物的合成实用性,并使用1 H-NMR 和13 C-NMR 光谱 (APT) 以及代表性化合物的 SC-XRD 研究来验证分子结构。 图形概要
    DOI:
    10.1007/s11164-023-05168-3
点击查看最新优质反应信息

文献信息

  • Verjuice as a green and bio-degradable solvent/catalyst for facile and eco-friendly synthesis of 5-arylmethylenepyrimidine-2,4,6-trione, pyrano[2,3-d]pyrimidinone and pyrimido[4,5-d]pyrimidinone derivatives
    作者:Niloufar Safari、Farhad Shirini、Hassan Tajik
    DOI:10.1007/s13738-018-1565-y
    日期:2019.4
    of the synthesis of 5-arylmethylenepyrimidine-2,4,6-triones, via Knovenagel condensation reaction between barbituric or thiobarbituric acid and aldehydes. Verjuice is also employed for the effective synthesis of pyrano[2,3-d]pyrimidinone derivatives via a three-component reaction of barbituric acid or its thio analogue, aldehydes and malononitrile. In the same way, pyrimido[4,5-d]pyrimidinone derivatives
    Verjuice(未成熟的葡萄汁)是一种有机酸的天然混合物,可通过pH值和TGA分析鉴定,可通过Knovenagel缩合有效地用于促进5-芳基亚甲基嘧啶-2,4,6-三酮的合成。巴比妥酸巴比妥酸与醛之间的反应。Verjuice还用于通过巴比妥酸或其代类似物,醛和丙二腈的三组分反应有效合成喃并[2,3- d ]嘧啶酮衍生物。同样,嘧啶基[4,5- d]嘧啶酮衍生物可简单地通过巴比妥酸,醛与硫脲在果汁中的反应来制备。这种绿色方法学具有显着的优势,包括操作简单,可接受的反应时间,易于后处理,高收率,避免在反应和后处理过程中使用任何昂贵的起始原料,挥发性和有害有机溶剂以及使用天然,低成本,可重复使用且可生物降解的催化剂。
  • DABCO-based ionic liquids: green and recyclable catalysts for the synthesis of barbituric and thiobarbituric acid derivatives in aqueous media
    作者:Narges Seyyedi、Farhad Shirini、Mohaddeseh Safarpoor Nikoo Langarudi
    DOI:10.1039/c6ra05878g
    日期:——
    the reaction of barbituric or thiobarbituric acid, malononitrile and aldehydes in the presence of this reagent and 1,4-disulfo-1,4-diazabicyclo[2.2.2]octane-1,4-diium chloride ([DABCO](SO3H)2(Cl)2) has been investigated. The structure of the products was characterized using IR, 1H NMR and 13C NMR spectroscopy. The present methodologies suggests several advantages such as ease of the preparation and
    一种新的,直接的方法,可通过使用1,4-二磺基-1,4-二氮杂双环[2.2.2]辛烷-1通过巴比妥酸及其代类似物与醛的反应来合成5-芳基巴比妥酸巴比妥酸,已经报道了作为有效催化剂的4-二硫酸氢二([DABCO](SO 3 H)2(HSO 4)2)。在该项目中,还通过在该试剂和1,4-二磺基-1,4-二氮杂双环[2.2]存在下,通过巴比妥酸巴比妥酸丙二腈和醛的反应制备喃并[2,3- d ]-嘧啶二酮。 .2]辛烷-1,4-氯化铵([DABCO](SO 3 H)2(Cl)2)已被调查。使用IR,1 H NMR和13 C NMR光谱对产物的结构进行表征。本方法论提出了若干优点,例如易于制备和处理催化剂,高收率,简单和绿色的方法,低成本,短的反应时间,易于后处理和在中作为绿色溶剂进行反应的预形成。
  • Introduction of organic/inorganic Fe<sub>3</sub>O<sub>4</sub>@MCM-41@Zr-piperazine magnetite nanocatalyst for the promotion of the synthesis of tetrahydro-4<i>H</i>-chromene and pyrano[2,3-<i>d</i>]pyrimidinone derivatives
    作者:Reyhaneh Pourhasan-Kisomi、Farhad Shirini、Mostafa Golshekan
    DOI:10.1002/aoc.4371
    日期:2018.7
    highly dispersed in the tetrahedral environment of silica framework and piperazine is successfully attached to the surface of the nanocatalyst in connection with zirconium. The prepared nanosized reagent (10–30 nm), shows excellent catalytic activity in the synthesis of tetrahydro‐4H‐chromene and pyrano[2,3‐d]pyrimidinone derivatives. All reactions are performed under mild and completely heterogeneous
    哌嗪修饰的Fe 3 O 4 @ MCM-41 @ Zr-MNPs易于制备,并使用傅里叶变换红外光谱(FT-IR),X射线粉末衍射(XRD),N 2吸附-解吸,透射电子显微镜进行表征( TEM),能量色散X射线(EDX),振动样品磁力法(VSM)和热重分析(TGA)技术。表征结果表明,高度分散在二氧化硅骨架和哌嗪的四面体环境中的Zr可以成功地附着在与相关的纳米催化剂表面。制备的纳米级试剂(10–30 nm)在四氢-4 H-色烯和喃[2,3- d]嘧啶酮衍生物。所有反应均在温和且完全异质的反应条件下进行,且反应时间短。另一方面,由于其超顺磁性,该催化剂可通过施加外部磁场容易地分离并重复使用多次。
  • Succinimidinium N-sulfonic acid hydrogen sulfate as an efficient ionic liquid catalyst for the synthesis of 5-arylmethylene-pyrimidine-2,4,6-trione and pyrano[2,3-d]pyrimidinone derivatives
    作者:Masoumeh Abedini、Farhad Shirini、Javad Mohammad-Alinejad Omran、Mohadeseh Seddighi、Omid Goli-Jolodar
    DOI:10.1007/s11164-015-2289-6
    日期:2016.5
    ([SuSA-H]HSO4) as a new ionic liquid is prepared and characterized using a variety of techniques, including infrared spectra (FT-IR), 1H and 13C NMR, scanning electron microscopy, a mass spectra method, as well as by Hammett acidity function. The prepared reagent is efficiently able to catalyze the preparation of 5-arylmethylene-pyrimidine-2,4,6-triones via the condensation of aldehydes and barbituric acid
    使用多种技术制备并表征了琥珀酰亚胺 N- 磺酸硫酸氢盐([SuSA-H] HSO 4),并使用多种技术进行了表征,包括红外光谱(FT-IR),1 H和13 C NMR,扫描电子显微镜,质谱方法以及Hammett酸度函数。通过醛和巴比妥酸的缩合,所制备的试剂能够有效地催化5-芳基亚甲基-嘧啶-2,4,6-三酮的制备。进一步的研究表明,醛与巴比妥酸丙二腈的缩合反应生成喃并[2,3- d 在该试剂的存在下,也可以有效地促进]嘧啶酮衍生物。本发明的方法具有几个优点,包括易于制备和处理催化剂,简单和容易的后处理,短的反应时间,产物的高产率和催化剂的可回收性。
  • Convenient and fast synthesis of various chromene pharmaceuticals assisted by highly porous volcanic micro-powder with nanoscale diameter porosity
    作者:Ali Maleki、Kobra Valadi、Saideh Gharibi、Reza Taheri-Ledari
    DOI:10.1007/s11164-020-04195-8
    日期:2020.9
    characterized by various analytical methods and suitably used for facilitating the organic synthesis reactions. Briefly, high reaction yield (99%) has been obtained in short reaction times (4 min) in the synthesis reactions of chromene pharmaceutical derivatives, through applying this highly efficient organometallic catalyst. From mechanistic aspect, effective electronic interactions between heteroatoms
    在本文中,基于火山的中孔催化体系通过各种分析方法精确表征,并且适合用于促进有机合成反应。简而言之,通过使用这种高效的有机属催化剂,在色烯药物衍生物的合成反应中,在短的反应时间(4分钟)内获得了高的反应产率(99%)。从机械方面来看,杂原子如氧与浮石微粒表面之间的有效电子相互作用为共价结合提供了合适的条件。作为火山浮石的主要优点,可以提及通过酸处理激活化学官能团后的高催化性能,磁性和完全自然的基础(生物相容性和生物降解性)。高度多孔的结构导致反应物截留在微小的孔中并被活化以进行共价结合。此外,作为该催化剂的另外的优异之处,可以提到颗粒分离中的极大便利性和极大的可重复使用性。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione